Evidence mapPaperPMID 40895902Full record

ArticleCureus2025

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor.

Mayuka Fukata, Tomomi Omura, Keiko Maeda, Takako Mori, Hiroyuki Kato, Masafumi Kuzuya

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mayuka FukataDepartment of Residency Training, Meitetsu Hospital, Nagoya, JPN.
Tomomi OmuraDepartment of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.
Keiko MaedaDepartment of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.
Takako MoriDepartment of Dermatology, Meitetsu Hospital, Nagoya, JPN.
Hiroyuki KatoDepartment of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.
Masafumi KuzuyaDepartment of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for the treatment of type 2 diabetes mellitus. Recently, their association with drug-induced bullous pemphigoid (BP) has attracted increasing attention. In this report, we present a case of an 84-year-old woman who developed BP after COVID-19 infection while taking a DPP-4 inhibitor. The temporal relationship between drug administration, viral infection, and onset of autoimmune disease indicates a possible interaction between COVID-19-induced immune dysregulation and DPP-4 inhibition. The coexistence of these factors may increase the risk of developing BP in older patients with diabetes, which warrants careful monitoring.

Indexed as

autoimmune diseasecovid-19dpp4 inhibitordrug-induced bullous pemphigoidolder patient

Identifiers

PMID40895902
PMCPMC12398674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.